S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

NeuroScientific Biopharmaceuticals Stock Price, News & Analysis (ASX:NSB)

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About NeuroScientific Biopharmaceuticals

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.


NSB Stock News Headlines

See More Headlines
Receive NSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroScientific Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.95 million
Book Value
A$0.03 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.73
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (ASX:NSB) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -